Kazia Therapeutics Files Form 6-K
Ticker: KZIA · Form: 6-K · Filed: Jun 5, 2025 · CIK: 1075880
Sentiment: neutral
Topics: reporting, foreign-private-issuer
Related Tickers: KZA
TL;DR
Kazia Therapeutics (KZA) filed a 6-K on 6/5/25. Standard reporting.
AI Summary
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on June 5, 2025. The company, headquartered in Sydney, NSW, is reporting for the month of June 2025. Kazia Therapeutics is incorporated in C3 and its fiscal year ends on June 30.
Why It Matters
This filing indicates ongoing reporting requirements for Kazia Therapeutics as a foreign private issuer, providing transparency to investors about its corporate status.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial or operational news that would inherently increase risk.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Novogen Ltd (company) — Former company name
- June 5, 2025 (date) — Filing date
- Sydney NSW (location) — Company headquarters
FAQ
What is the primary purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the company has made or is required to make public pursuant to the laws of its home country.
When was Kazia Therapeutics Limited previously known as?
Kazia Therapeutics Limited was formerly known as Novogen Ltd, with a date of name change in 19981228.
Where is Kazia Therapeutics Limited's principal executive office located?
The principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
What is Kazia Therapeutics Limited's fiscal year end?
Kazia Therapeutics Limited's fiscal year ends on June 30.
What SEC Act does this filing fall under?
This filing is made pursuant to the Securities Exchange Act of 1934.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 5, 2025 regarding KAZIA THERAPEUTICS LTD (KZIA).